NeuroVive: Interim Report 1 Jan. 2013 till 30 Jun. 2013

Milestones achieved consolidate positioning in mitochondrial medicine

Six months (1 Jan. 2013 – 30 Jun. 2013)

  • Net revenues  were SEK 5,335,000 (0) and other operating income was SEK 863,000      (319,000).
  • Loss before tax was SEK -6,206,000 (-6,871,000).
  • Earnings per share* were SEK -0.39 (-0.41).
  • Diluted earnings  per share** were SEK -0.39 (-0.41).

Second quarter (1 Apr. 2013 – 30 Jun. 2013)

  • Net revenues were SEK 5,335,000 (0) and other operating income was SEK 159,000      (310,000).
  • Loss before tax was SEK -1,467,000 (-4,056,000).
  • Earnings per share* were SEK -0.15 (-0.24).
  • Diluted earnings per share** were SEK-0.15 (-0.24).

* Profit/loss for the period divided by the average number of shares before dilution at the end of the period.
**Profit/loss for the period divided by the average number of shares after dilution at the end of the period.

Business highlights in the second quarter of 2013

  • 10thof April, NeuroVive had its IPO on NASDAQ OMX Small Cap, with stock symbol NVP.

  • Patient 700 of totally 972 have been enrolled to its multinational phase III trial on the company’s pharmaceutical CicloMulsion® (CIRCUS trial) or treating reperfusion injury in myocardial infarction.

  • First patient have been enrolled to a clinical phase IIa trial on the company’s pharmaceutical NeuroSTAT® for treating traumatic brain damage. This trial covers a total of 20 patients and is being conducted at  the neurology clinic of the Danish National Hospital in Copenhagen.

  • In June, NeuroVive signed a collaboration agreement with Isomerase      Therapeutics to develop the molecules the company acquired from Biotica Ltd. in March 2013. The focus of this partnership is cell protection in traumatic brain damage, heart attack and in the new product segment of anti-viral      indications in the form of a new product designated NVP018/BC556.

  • NeuroVive’s subsidiary NeuroVive Pharmaceutical Asia Ltd. received      SEK 5.3 m(RMB 5 m) as a first milestone payment from NeuroVive’s collaboration partner in China, Sihuan Pharmaceutical.

Read the Interim Report here: NeuroVive Interim Report 2013-01-01_2013-06-30 


About Us

Abliva AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects. Abliva’s ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under the NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). Abliva is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).